MT II

Melanotan-II was initially developed at the University of Arizona in the 1990s. The primary goal was to create a compound that could stimulate the production of melanin in the skin, thereby providing a protective tan without the need for exposure to harmful ultraviolet (UV) radiation from the sun . This was particularly aimed at reducing the risk of skin cancer caused by UV exposure.

Melanotan-II works by mimicking the action of α-MSH. When administered, it binds to melanocortin receptors on melanocytes, leading to increased production of melanin. This results in a darker skin pigmentation, which can occur within days of administration . Additionally, Melanotan-II has been found to have other effects, such as suppressing appetite and promoting weight loss, which some users find desirable .

Despite its potential benefits, Melanotan-II is not without risks. Medical experts have raised serious safety concerns about its use. One of the most significant risks is its potential to induce melanoma, the deadliest form of skin cancer. By stimulating melanocytes, Melanotan-II can cause abnormal proliferation of these cells, potentially leading to cancer .

Other reported side effects include:

• Uneven pigmentation
• New moles or darkening of existing moles
• Nausea
• Flushing
• Increased libido

Melanotan-II is not approved for use by any major health regulatory agencies, including the FDA (U.S. Food and Drug Administration) and the TGA (Therapeutic Goods Administration) in Australia. It is considered an unlicensed and largely untested drug, and its sale and distribution are illegal in many countries .